Germany’s Merck KGaA has agreed to buy SpringWorks Therapeutics, adding the US biotech’s portfolio of cancer and rare disease ...

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

Sullivan & Cromwell is acting for longtime client Merck in its $3.9bn acquisition of US biotech company SpringWorks ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share ... coming after it paid Chinese biotech Abbisko Therapeutics $70 million upfront for rights to pimicotinib, a drug in ...

In the vehicles’ strongest showing since early 2022, there were eight new SPACs from April 28 through May 5. Of those eight, ...

Merck KGaA to buy Springworks for $3.9 billion Merck KGaA (OTCPK:MKGAF) is set to acquire SpringWorks Therapeutics (SWTX) for ...

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

CRAIG BETTENHAUSEN Novartis will buy the oligonucleotide start-up Regulus Therapeutics for $800 million up front. Shareholders may also receive milestone payments contingent on United States ...

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...

Recent developments in health highlight key agreements between countries, drug approvals, corporate revenue growth, and ...